Due to the production and marketing of non-compliant chrysanthemums, the pharmaceutical company ate nearly 600,000 yuan fine!

【Pharmaceutical Network Industry Dynamics】Drugs are special commodities related to human health and safety, and their quality should meet the corresponding requirements in order to circulate and market in the market
.

In order to ensure the quality and safety of drugs, in recent years, relevant departments have frequently issued policies and strict supervision to promote the development of the pharmaceutical industry in the direction of
standardization.

However, drug safety problems have been emerging for a long time, among them, Chinese medicine tablets are unqualified "regular customers" of relevant departments due to the backward standards of some Chinese herbal medicines, unscientific cultivation of traditional Chinese medicines, many small workshops with low prices and low quality, and the difficulty of accurate supervision
.

On September 15, the State Food and Drug Administration issued a notice that 17 batches of drugs did not meet the regulations, and the unqualified drugs involved 8 batches of chrysanthemums, 1 batch of madder, and 4 batches of comfrey
.

The Anhui Provincial Food and Drug Administration also recently issued a notice that a Chinese medicine tablet company in Bozhou City was fined nearly 600,000 yuan
for producing and selling chrysanthemums that did not meet the regulations.

It is reported that the company has been a "habitual offender", and in the past year, it has been punished with huge sums of money for the production and sale of
inferior drugs.

On July 20, the Heilongjiang Provincial Food and Drug Administration issued an administrative penalty decision, in which a Chinese medicine tablet company in the province was punished for producing and selling inferior Chinese medicine tablets "Sea Wind Vine", which was punished without illegal gains and warnings
.

In addition, since 2022, the drug regulatory departments in Sichuan, Henan, Guangdong and other places have successively exposed some enterprises
that produce and sell unqualified Chinese medicine tablets.

In accordance with the relevant provisions of the new version of the Drug Administration Law, those who produce and sell inferior drugs will be subject to confiscation of illegal gains, and a fine of 2.
5 times the value of drugs illegally produced and sold (if the value of drugs illegally produced or sold is less than 100,000 yuan, it is calculated according to 100,000 yuan), as well as the penalty
of confiscating and recalling the batch of inferior drugs.

Judging from the amount of fines imposed on enterprises that fail to pass the sampling of traditional Chinese medicine tablets above, ranging from tens of thousands of yuan to hundreds of thousands of yuan
.

This is undoubtedly "because of small and small losses" for small and medium-sized enterprises with meager profits, and the gains are not worth the losses, which is enough to wake up the industry and remind the drinking enterprises to abandon the fluke psychology and take the road of
compliance production and marketing.

Overall, with the continuous efforts of relevant departments, the production quality of Chinese herbal medicines is constantly improving
.

The 2021 National Drug Sampling Annual Report of the State Food and Drug Administration shows that the total pass rate of sampling of Chinese medicine tablets has reached 98%.
The Chinese medicine tablet industry is a pillar industry of China's traditional Chinese medicine industry, and the market for Chinese medicine tablets is huge
under the background of the intensification of the aging population and the frequent release of favorable policies.

According to the "2021 Blue Book of National Chinese Medicine Supervision", by the end of 2021, there are 2225 proprietary Chinese medicine manufacturers and 2023 Chinese medicine tablets manufacturers in China
.

According to other data, in 2021, the operating income of the Chinese medicine tablet industry has reached 205.
6 billion yuan, an increase of 13.
7% year-on-year, and the profit increased by 102.
4%.
At present, the collection of traditional Chinese medicine tablets is being accelerated
.

In addition, the "National Proprietary Chinese Medicine Alliance Procurement Announcement" was also released not long ago, and the document clarified that 30 provinces (excluding Hunan, Fujian, Hong Kong, Macao and Taiwan) will form a national joint procurement office for proprietary Chinese medicines, led
by the Hubei Medical Insurance Bureau.

The industry believes that the collection of mining through the price for volume, or to the industry to bring a big reshuffle, and the premise of entering the collection is the need to ensure quality, therefore, the film enterprises need to regard the quality of the problem as the top priority, in order to get the "admission ticket"
into the game.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.